Pancreatic Cancer News and Research

RSS

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.

Research reveals the cellular origin of cancer-associated fibroblasts

A type of cell that plays a key role in pancreatic cancer can trace its origin back to a structure that forms during embryonic development, new research at MUSC Hollings Cancer Center shows.

20 Jan 2023

Study reveals how most-resistant pancreatic cancer cells defy treatment

Pancreatic cancer is the third deadliest cancer in the United States, after lung and colorectal, though far less common.

19 Jan 2023

Cancer mortality in the U.S. has declined 33% since the 90s

The American Cancer Society has recently published the statistics of cancer incidence and mortality for 2023 in CA: A Cancer Journal for Clinicians.

17 Jan 2023

New molecular pathway critical to the initiation of pancreatic tumors discovered

Researchers at University of California San Diego School of Medicine have discovered a molecular pathway critical to the initiation of pancreatic tumors.

16 Jan 2023

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

11 Jan 2023

UC researcher focuses on studying how gene mutations help pancreatic cancer grow

Only about 11% of people will survive five years after the detection of advanced pancreatic cancer. Such a low rate of success in treating pancreatic cancer is due to its late detection and an incomplete understanding of the disease development processes.

10 Jan 2023

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Immunotherapy is a way of treating cancer by reprogramming the patient's immune system to attack their tumor.

10 Jan 2023

Clinically relevant biomarker strategies in drug development

In this interview, NewsMedical speaks with Dr. Justin Devine and Dr. Nicholas Woudberg about biomarkers, their importance for drug development as well as the potential they have when it comes to machine learning.

From Synexa Life Sciences 9 Jan 2023

Historic agreement to accelerate trials into vaccines for cancer and wider diseases

Trials into vaccines for cancer and wider diseases will accelerate after the government reached a historic agreement with a leading biopharmaceutical firm to bring revolutionary research to England.

5 Jan 2023

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis and limited treatment options.

3 Jan 2023

Researchers identify novel gene mechanism in most aggressive kidney cancers

In a new study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway with loss of the tuberous sclerosis complex (TSC) tumor suppressor gene.

3 Jan 2023

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers.

22 Dec 2022

Sotorasib achieves meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

In the Phase I/II CodeBreaK 100 trial, the KRAS G12C inhibitor sotorasib achieved meaningful anticancer activity with an acceptable safety profile in heavily pretreated patients with KRAS G12C-mutated metastatic pancreatic cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

21 Dec 2022

Pancreatic Cancer News and Research

Further Reading

Research reveals the cellular origin of cancer-associated fibroblasts

Study reveals how most-resistant pancreatic cancer cells defy treatment

Cancer mortality in the U.S. has declined 33% since the 90s

New molecular pathway critical to the initiation of pancreatic tumors discovered

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

UC researcher focuses on studying how gene mutations help pancreatic cancer grow

Drug combination elicits efficacious anti-tumor immunity against immunotherapy-resistant cancers

Clinically relevant biomarker strategies in drug development

Historic agreement to accelerate trials into vaccines for cancer and wider diseases

Novel triple immunotherapy combination improves anti-tumor responses in preclinical models of pancreatic cancer

Researchers identify novel gene mechanism in most aggressive kidney cancers

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

Sotorasib achieves meaningful anticancer activity in patients with KRAS G12C-mutated metastatic pancreatic cancer

PCOS increases risk of pancreatic cancer

New method combines injectable radioactive gel with systemic chemotherapy to treat pancreatic cancer

BGI cares - 2022 social responsibilities in review

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Experimental therapy shows promise as treatment for metastatic colon cancer in preclinical models

Researchers identify a new target gene in pancreatic ductal adenocarcinoma

What is the incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir?

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News